The objective of the International Master Contractor (IMC) is to provide core technical and administrative capacity that is capable of supporting the NIAID in evaluating the safety, immunogenicity and efficacy of HIV vaccines and other biomedical technologies in population groups from countries outside of the United States and its territories. The contractor will provide technical and administrative services which are capable of developing research protocols, organizing and conducting public solicitations for competitive bids to conduct research trials, and establishing subcontracts to conduct baseline/feasibility studies, Phase I/II and Phase III efficacy trials of candidate HIV vaccines and other biomedical interventions. The IMC will provide these services under the guidance of the NIAID and in coordination with management and technical support of the HIV Vaccine Evaluation Network: (HIVNET). The HIVNET management structure includes an Advisory Working and Steering Group which provide oversight on polices of the NIAID. Technical support from the HIVNET includes a Central Laboratory Contractor, a contractor for a Statistical and Clinical Coordinating Center, and a Central Repository contractor. Through the HIVNET, administrative procedures and research activities of the IMC will be coordinated with parallel services of a Domestic Master Contractor (DMC) which is charged with supporting research trials on the efficacy of HIV vaccines and other biomedical interventions in population groups in the United States. The overall goal of the HIVNET, the IMC and the DMC is to expedite the development and testing of vaccines and other biomedical technologies which are capable of preventing the transmission of HIV or of diminishing the disease impact of an HIV infection.

Project Start
1993-09-30
Project End
1998-09-29
Budget Start
1995-06-27
Budget End
1996-09-29
Support Year
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Family Health International
Department
Type
DUNS #
067180786
City
Research Triangle Park
State
NC
Country
United States
Zip Code
27713
Owor, Maxensia; Mwatha, Anthony; Donnell, Deborah et al. (2013) Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. J Acquir Immune Defic Syndr 64:464-71
Sahastrabuddhe, Sushant; Gupta, Amita; Stuart, Elizabeth et al. (2012) Sexually transmitted infections and risk behaviors among transgender persons (Hijras) of Pune, India. J Acquir Immune Defic Syndr 59:72-8
Kovalchik, Stephanie A (2012) Mother's CD4+ count moderates the risk associated with higher parity for late postnatal HIV-free survival of breastfed children: an individual patient data meta-analysis of randomized controlled trials. AIDS Behav 16:79-85
Taha, Taha E; Dadabhai, Sufia S; Sun, Jin et al. (2012) Child mortality levels and trends by HIV status in Blantyre, Malawi: 1989-2009. J Acquir Immune Defic Syndr 61:226-34
Taha, Taha E; Dadabhai, Sufia S; Rahman, M Hafizur et al. (2012) Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in Malawi. Pediatr Infect Dis J 31:481-6
Sahay, Seema; Gupte, Nikhil; Brahme, Radhika G et al. (2011) Predictors of retention among men attending STI clinics in HIV prevention programs and research: a case control study in Pune, India. PLoS One 6:e17448
Laeyendecker, Oliver; Latimore, Amanda; Eshleman, Susan H et al. (2011) The effect of sample handling on cross sectional HIV incidence testing results. PLoS One 6:e25899
Cousins, Matthew M; Laeyendecker, Oliver; Beauchamp, Geetha et al. (2011) Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One 6:e27211
James, Maria M; Wang, Lei; Musoke, Philippa et al. (2011) Association of HIV diversity and survival in HIV-infected Ugandan infants. PLoS One 6:e18642
Onyango-Makumbi, Carolyne; Bagenda, Danstan; Mwatha, Antony et al. (2010) Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr 53:20-7

Showing the most recent 10 out of 113 publications